Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended	12 Months Ended
	Sep. 30, 2019 USD ($)	Dec. 31, 2021 USD ($) Segment	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2017 USD ($)	May 31, 2021 USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Number of operating segment | Segment		1
Cash, cash equivalents and marketable securities		$ 546,000,000.0
Principal amount		225,500,000				$ 225,500,000
Debt interest rate						2.50%
Repayments of debt		190,200,000
Net Proceeds to Pay the Costs		27,200,000
Long-term debt, net of debt discount		$ 5,010,000	$ 1,094,000
Debt maturity date		May 15, 2026
Net income (loss)		$ 76,713,000	(75,240,000)	$ (152,600,000)
Foreign Currency Transaction Gain (Loss), Unrealized		2,500,000	2,700,000	500,000
Currency transaction gain (loss)		$ 900,000	$ 800,000	200,000
Percentage of long lived assets		43.00%	57.00%
Inventory reserves		$ 0	$ 0
Inventory write-off		2,588,000
Accelerated depreciation related to certain long-lived assets	$ 3,000,000.0	0	0	3,000,000.0
Goodwill impairment			$ 0	0	$ 0
Increase in product revenue		$ 800,000
Product | Credit Concentration Risk
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Concentration risk, customer		one	one
Product | Trade Receivable | Customer Concentration Risk [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Concentration risk, percentage		94.00%	100.00%
HEPLISAV-B
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Net income (loss)		$ 76,700,000
Inventory write-off			$ 0	$ 0
HEPLISAV-B | Credit Concentration Risk
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Concentration risk, customer		three	three
HEPLISAV-B | Trade Receivable | Credit Concentration Risk
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Concentration risk, percentage		76.00%	86.00%
Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Cash equivalents original maturity period		3 months
Expected period of payment to be received		1 year
Dynavax GmbH
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Cumulative translation adjustment		$ 2,300,000	$ 200,000